Pfizer Terminates Gene Therapy Deal with Sangamo: Implications for Hemophilia
In a surprising move, Pfizer has decided to halt the development of a hemophilia A gene therapy that it had licensed from Sangamo Therapeutics. This decision could have significant implications for Sangamo’s future in the biotech industry.
Pfizer’s initial plan was to bring the experimental treatment to regulators. However, the sudden abandonment of this project is a setback for both companies. While this move may not heavily impact Pfizer or patients in the short term, it raises questions about the future of gene therapies for rare diseases like hemophilia.
The Impact on Sangamo and Pfizer
For Sangamo, the termination of this gene therapy deal is a major blow. The biotech company was relying on this treatment to potentially turn their fortunes around. Under the 2017 agreement between Sangamo and Pfizer, the California-based biotech was supposed to receive $220 million in milestones. With Pfizer backing out, Sangamo’s financial and strategic plans are now in question.
On the other hand, Pfizer’s decision to abandon the hemophilia A gene therapy may not have a significant financial impact on the pharma giant. Despite this setback, Pfizer remains a key player in the biotech industry. However, this move could signal a shift in their approach to gene therapies and rare diseases.
The Future of Gene Therapies for Hemophilia
The approval of another gene therapy for hemophilia A last year did not generate much interest due to the high standard of care already available. Additionally, gene therapies are not yet considered curative for this condition. With Pfizer’s exit from the gene therapy space, the future of these treatments for hemophilia remains uncertain.
Expert Perspective
According to Jason Mast, a general assignment reporter at STAT, the termination of the gene therapy deal between Pfizer and Sangamo raises important questions about the viability of gene therapies for rare diseases. Mast emphasizes the need for continued research and development in this area to provide better treatment options for patients with hemophilia and other genetic disorders.
